Charles River Laboratories International (NYSE:CRL) Rating Lowered to “Hold” at Wall Street Zen

Charles River Laboratories International (NYSE:CRL) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms have also commented on CRL. Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a report on Thursday. Barclays dropped their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Evercore upped their target price on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $205.77.

Charles River Laboratories International Trading Up 3.1%

Shares of NYSE CRL opened at $169.26 on Friday. The firm’s 50 day moving average price is $200.37 and its 200-day moving average price is $179.34. The company has a market cap of $8.33 billion, a PE ratio of -57.18, a P/E/G ratio of 4.86 and a beta of 1.63. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same quarter last year, the firm earned $2.66 earnings per share. The firm’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts expect that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Several large investors have recently added to or reduced their stakes in the business. Tema Etfs LLC purchased a new stake in Charles River Laboratories International during the fourth quarter valued at approximately $26,000. Neo Ivy Capital Management purchased a new stake in shares of Charles River Laboratories International in the 2nd quarter worth $29,000. Rothschild Investment LLC increased its stake in shares of Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in Charles River Laboratories International in the 3rd quarter worth $31,000. Finally, Los Angeles Capital Management LLC purchased a new position in Charles River Laboratories International during the fourth quarter valued at $42,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.